OPKO Health (OPK +0.8%) announces the completion of the last patient visit in its Phase 3 clinical trial evaluating once-weekly somatrogon (hGH-CTP) for the treatment of children with growth hormone deficiency.
The primary endpoint is height velocity at week 52. Topline results should be available next quarter.
Collaboration partner Pfizer (PFE +1.4%) is responsible for regulatory filings and commercialization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.